ReviewCNS drugs2017
Safinamide: A Review in Parkinson's Disease.
Review in CNS drugs, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Efficacy and safety of perampanel in Parkinson's disease. A systematic review with meta-analysis.Journal of neurology · 2018Pooled it
- 3-SFChemical science · 2026Article
- In Vivo Electrochemical Monitoring of Safinamide Pharmacokinetics in the Brain Explores Its Correlation With Vision-Related Neuronal Activity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Efficacy of Safinamide in Early-Stage Parkinson's Disease: A Pilot Evaluation of Motor Symptom Improvement.Journal of movement disorders · 2025Article
- Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.Brain sciences · 2025Article
- Beyond expectations: safinamide's unprecedented neuroprotective impact on acute spinal cord injury.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Article
- Novel and experimental therapeutics for the management of motor and non-motor Parkinsonian symptoms.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Review
- Inhibition of Monoamine Oxidases by Pyridazinobenzylpiperidine Derivatives.Molecules (Basel, Switzerland) · 2024Article
- A Novel MAO-B/SSAO Inhibitor Improves Multiple Aspects of Dystrophic Phenotype inAntioxidants (Basel, Switzerland) · 2024Article
- Recent Trends in Nanomaterial Based Electrochemical Sensors for Drug Detection: Considering Green Assessment.Current topics in medicinal chemistry · 2024Review
- Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.Neural regeneration research · 2024Review
- Two weeks dose range-finding and four weeks repeated dose oral toxicity study of a novel reversible monoamine oxidase B inhibitor KDS2010 in cynomolgus monkeys.Toxicological research · 2023Article
- Rivastigmine-Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases.International journal of molecular sciences · 2023Article
- Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease.Advances in neurobiology · 2023Review
- An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.Current neuropharmacology · 2023Review
- Impact of Safinamide on Patient-Reported Outcomes in Parkinson's Disease.Patient related outcome measures · 2023Review
- Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.Cells · 2022Review
- Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease.NPJ Parkinson's disease · 2022Review
- Study on the Neuroprotective, Radical-Scavenging and MAO-B Inhibiting Properties of New Benzimidazole Arylhydrazones as Potential Multi-Target Drugs for the Treatment of Parkinson's Disease.Antioxidants (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Safinamide (Xadago
Indexed as
Identifiers
28110399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.